glp 1 agonist for type 1 diabetes Targeting GLP-1, GIP & GCG in Obesity and 2 Research Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)

Established risk factors include: History of pancreatitis: Patients with prior episodes face substantially higher recurrence risk and require careful consideration before initiating GLP-1 therapy Gallstone disease: Cholelithiasis and biliary sludge can precipitate pancreatitis, particularly during periods of rapid weight loss Hypertriglyceridemia: Triglyceride levels 1,000 mg/dL significantly increase pancreatitis risk, with risk beginning to rise at levels 500 mg/dL Excessive alcohol consumption: Alcohol remains one of the most common pancreatitis triggers and may interact with metabolic changes induced by GLP-1 medications Obesity and rapid weight loss: While weight reduction is therapeutic, very rapid loss may increase gallstone formation Warning signs of acute pancreatitis that patients should recognize include severe, persistent abdominal pain, typically in the upper abdomen and often radiating to the back

Cognitive function either improved or remained stable

Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials

Mojsov S, Weir GC, and Habener JF

Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management

Side-effects and possible issues with long-term use of these novel agents have yet to be fully evaluated